Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003768 · ClinicalTrials.gov registry record · Phase 1

Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors

A Phase 1 study, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target

NCT00003768 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 25 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003768, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combretastatin A4 phosphate in treating patients who have advanced solid tumors that have not responded to previous therapy.

Interventions

  • DRUG fosbretabulin disodium

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 1998-09
Est. Completion 2001-07
Phase Phase 1

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT00003768

The ClinicalTrials.gov registry entry for NCT00003768 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which fosbretabulin disodium is the first listed.

NCT00003768 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00003768 about?

NCT00003768 is a clinical study titled "Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combretastatin A4 phosphate in treating patients who have advanced solid tumors that have not responded to previous therapy.

What is the current status of trial NCT00003768?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1998-09. Estimated completion is 2001-07.

What interventions are being tested in trial NCT00003768?

The interventions under investigation include: fosbretabulin disodium (DRUG).

Who is sponsoring clinical trial NCT00003768?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.